השוואת שיטות

	איכות חיים באפילפסיה-89 (QOLIE-89)	סולם רנקין מותאם (mRS)	שאלון איכות חיים בטרשת נפוצה-54 (MSQOL-54)
תחום	נוירולוגיה	נוירולוגיה	נוירולוגיה
משפחה	Process / pipeline	Process / pipeline	Process / pipeline
שנת המקור	1995	1988	1995
הוגה השיטה	Orrin Devinsky, NYU	Rankin scale original (Rankin, 1957); modified version by van Swieten et al.	Barbara G. Vickrey, UCLA
סוג	Self-report questionnaire	Clinician-rated ordinal scale	Self-report questionnaire
מקור מכונן	Devinsky, O., Vickrey, B. G., Cramer, J., Edwards, B., Perrine, K., Hamberger, M. J., & Towle, V. L. (1995). Development of the Quality of Life in Epilepsy Inventory. Epilepsia, 36(11), 1089-1104.	van Swieten, J. C., Koudstaal, P. J., Visser, M. C., Schouten, H. J., & van Gijn, J. (1988). Interobserver agreement for the assessment of handicap in stroke patients. Stroke, 19(5), 604-607.	Vickrey, B. G., Hays, R. D., Genovese, B. J., Myers, L. W., & Ellison, G. W. (1995). Outcomes in Multiple Sclerosis: The Multiple Sclerosis Quality of Life-54 Scale. Health Psychology, 14(1), 34-42.
כינויים	QoLIE-89	mRS, Rankin Scale, Modified Rankin	MS QoL-54
קשורות	3	4	4
תקציר	The QOLIE-89 is a comprehensive disease-specific quality-of-life instrument developed specifically for people with epilepsy. Introduced by Devinsky and colleagues in 1995, it captures the broad impact of epilepsy on physical, emotional, social, and cognitive functioning. With 89 items organized into 17 distinct domains, it remains one of the most detailed QoL assessments for epilepsy and is widely used in clinical trials, health services research, and outcome monitoring.	The Modified Rankin Scale is a simple 0-6 ordinal measure of global disability or dependency in patients with stroke and other neurological conditions. Originally developed by Rankin in 1957 and modified by van Swieten and colleagues in 1988, it remains the most widely used global disability outcome in stroke clinical trials and clinical practice. Its simplicity, brevity, and strong prognostic association make it the gold standard for acute stroke outcome measurement and is mandated as a primary endpoint in virtually all stroke therapeutic trials.	The MSQOL-54 is a disease-specific quality-of-life instrument designed to assess the physical and mental burden of multiple sclerosis on patients' daily functioning and well-being. Developed by Vickrey and colleagues in 1995, it combines the widely-used SF-36 generic health questionnaire with 18 MS-specific items to provide comprehensive measurement of QoL in MS populations. This scale is a cornerstone tool in MS clinical research and patient monitoring.